# Kaleido

> Kaleido is a small, discreet, customizable insulin patch pump built by Dutch medtech company ViCentra to make living with diabetes less of a burden. Designed to look and feel like a lifestyle product rather than a clinical device, Kaleido pairs with Diabeloop's self-learning algorithm and the Dexcom CGM to enable hybrid closed-loop, app-controlled insulin delivery. With more than 3,500 users in Europe and an $85M+ Series D raised in 2025, the company is scaling manufacturing of its next-generation Kaleido 2 and preparing for entry into the United States.

- **Founded:** 2013
- **Headquarters:** Utrecht, Netherlands
- **Founders:** Tim Oakes (Co-founder & CTO (award-winning design engineer; father has type 1 diabetes)), Joseph Cefai (Co-founder (exited the company in 2016))
- **Team size:** ≈200 employees
- **Products:** Kaleido insulin patch pump, Kaleido 2, Hybrid Closed Loop system, Mobile app & handset
- **Notable:** Built the smallest, thinnest, lightest, most precise insulin patch pump in its class, Doses insulin with precision as small as 0.5 microliters, Grew to more than 3,500 users across Europe

## Products & services

- **Kaleido insulin patch pump** — A compact (50 x 35 x 12.5mm), lightweight, discreet reusable patch pump that delivers insulin with precision down to 0.5 microliter doses. Customizable with ten color shells, multiple tubing lengths, and pump/body patch options.
- **Kaleido 2** — Next-generation patch pump described as the world's smallest, lightest, lifestyle-oriented insulin patch pump in its class, slated to launch in Europe (Germany and the Netherlands) in 2026.
- **Hybrid Closed Loop system** — Kaleido paired with Diabeloop's self-learning DBLG1/DBLG2 automated insulin delivery algorithm and the Dexcom CGM, enabling fully automated, smartphone-controlled insulin delivery.
- **Mobile app & handset** — Companion handset and mobile app for bolus calculation, meal announcement, insulin-on-board tracking, and personalized insulin therapy.

## Achievements

- Built the smallest, thinnest, lightest, most precise insulin patch pump in its class
- Doses insulin with precision as small as 0.5 microliters
- Grew to more than 3,500 users across Europe
- Closed an $85M+ Series D in 2025 (extended toward ~$98M)
- Launched a hybrid closed-loop system with Diabeloop and Dexcom
- Named among TIME's World's Top HealthTech Companies of 2025

## Latest updates

- **2026-01** — ViCentra extended its Series D toward roughly $98M to commercialize Kaleido and support a US launch.
- **2025-09** — Closed $85M (€72.4M) Series D led by Innovation Industries to scale manufacturing and prepare Kaleido 2 and US entry.
- **2026** — Planned European launch of next-gen Kaleido 2 with Diabeloop's DBLG2 algorithm and Dexcom G7, debuting in Germany and the Netherlands.

## Links

- Website: https://hellokaleido.com
- LinkedIn: http://www.linkedin.com/company/hellokaleido
- Twitter/X: https://twitter.com/HeyKaleido
- Facebook: https://facebook.com/HeyKaleido

---

Profile page: https://yespress.io/kaleido
Published by YesPress — https://yespress.io
Last updated: 2026-06-14